Immix Biopharma (IMMX) Free Cash Flow (2021 - 2026)

Immix Biopharma has disclosed Free Cash Flow across 6 years of filings, most recently posting -$9.9 million for Q1 2026.

• Free Cash Flow for Q1 2026 came in at -$9.9 million, down 462.49% year-over-year; the trailing twelve-month figure through Mar 2026 was -$32.8 million (down 144.61% YoY), and the FY2025 annual result was -$24.7 million, down 56.37% from the prior year.
• Free Cash Flow came in at -$9.9 million for Q1 2026 at Immix Biopharma, up from -$11.2 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of -$547066.0 in Q2 2022 to a low of -$11.2 million in Q4 2025.
• The 5-year median for Free Cash Flow is -$3.5 million (2023), against an average of -$4.1 million.
• Across the five-year window, Free Cash Flow slumped 2781.24% in 2022 and jumped 57.55% in 2025, its largest moves.
• Immix Biopharma's Free Cash Flow stood at -$3.9 million in 2022, then jumped by 31.08% to -$2.7 million in 2023, then climbed by 26.29% to -$2.0 million in 2024, then tumbled by 464.44% to -$11.2 million in 2025, then grew by 11.93% to -$9.9 million in 2026.
• The last three Free Cash Flow figures came in at -$9.9 million (Q1 2026), -$11.2 million (Q4 2025), and -$6.3 million (Q3 2025), per Business Quant data.